Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Invega Trinza

- PMLiVE

J&J adds Manchester to partnering network

Adds satellite office for London innovation hub

EU flag

J&J gets EU green light for novel TB drug

Sirturo approved to treat multidrug resistant form of the disease

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

J&J’s Care4Today brand joins Twitter

Firm's Janssen Healthcare Innovation unit also makes its debut on the social network

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

- PMLiVE

Janssen Invokana combination recommended for European approval

Drug adds metformin to the firm's new SGLT2 inhibitor

- PMLiVE

J&J sets new pharma standard for sharing clinical trial data

Chooses Yale to act as independent trial data request review body

- PMLiVE

Janssen announces new group to tackle global health

Will implement R&D and access strategies to support areas with unmet public health need

- PMLiVE

Otsuka/Lundbeck say brexpiprazole works in phase III trial

On course as successor to antipsychotic Abilify

J&J expected to make best use of digital in 2014

Company's strong approach to marketing strategy praised in Digital Futures 2014 survey

Roche Basel Switzerland

Setback for Roche as schizophrenia candidate fails studies

 Bitopertin misses primary endpoints in two phase III trials

- PMLiVE

J&J sells diagnostics unit to private equity firm

Ortho-Clinical Diagnostics acquired by the Carlyle Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links